dengue virus vaccine (Dengvaxia)
Jump to navigation
Jump to search
Indications
- prevention of dengue fever[1]
- live attenuated vaccine for prevention of all 4 dengue serotypes in young persons 9-16 years with lab-confirmed prior dengue infection & who live in endemic areas (American Samoa, Guam, Puerto Rico, Virgin Islands)
Contraindications
- should not be used in people without previous dengue infection
Dosage
- 3 injections at 0, 6, & 12 months[5]
Adverse effects
- headache, myalgia, arthralgia fatigue, injection site pain, low-grade fever
Notes
- 56-76% effective
- efficacy against symptomatic virologically confirmed dengue 61%
- efficacy against severe dengue > 90%
- efficacy against hospitalization 80%
- not effective against serotype 2
- efficacy lower in younger than in older children[3]
- tetravalent dengue vaccine (CYD-TDV) protects against severe virologically-confirmed dengue for 5 years in persons who had exposure to dengue before vaccination[4],
- evidence of a higher risk for severe dengue in vaccinated persons who had not been exposed to dengue[4]
- appears to act like a first dengue infection, such that a subsequent infection can result in severe dengue, thus not for dengue niave persons
More general terms
Additional terms
References
- ↑ 1.0 1.1 Capeding MR et al Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. The Lancet, Early Online Publication, 11 July 2014 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25018116 <Internet> http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2961060-6/abstract
Wilder-Smith A Dengue vaccines: dawning at last? The Lancet, Early Online Publication, 11 July 2014 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25018119 <Internet> http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2961142-9/fulltext - ↑ Villar L et al Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America. N Engl J Med. November 3, 2014 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25365753 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1411037
- ↑ 3.0 3.1 Hadinegoro SR et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 2015 Jul 27 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/26214039 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1506223
Simmons CP. A candidate dengue vaccine walks a tightrope. N Engl J Med 2015 Jul 27 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/26214040 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMe1509442 - ↑ 4.0 4.1 4.2 Sridhar S, Luedtke A, Langevin E. Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy. N Engl J Med. June 13, 2018 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29897841 https://www.nejm.org/doi/full/10.1056/NEJMoa1800820
- ↑ 5.0 5.1 FDA news release. May 1, 2019 First FDA-approved vaccine for the prevention of dengue disease in endemic region. https://www.fda.gov/news-events/press-announcements/first-fda-approved-vaccine-prevention-dengue-disease-endemic-regions